Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ509J)

• Drug Name: Alicaforsen Drug Info
• Synonyms: Alicaforsen [INN]; ISIS 2302; ISIS-2302; Intercellular adhesion molecule-1 antisense oligodeoxynucleotide; DNA, d((R)-P-thio)(G-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A); Deoxyribonucleic acid, d((R)-P-thio)(G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A)

Indication

Disease Entry	ICD 11	Status	REF
Lleum inflammation	1A40.0	Phase 3	[1]
Crohn disease	DD70	Phase 2	[2]
Ulcerative colitis	DD71	Phase 2	[2]

• Therapeutic Class: Antisense
• Cross-matching ID:
  PubChem CID: 16197725
  CAS Number: CAS 185229-68-9
  TTD Drug ID: DMQ509J

Molecule-Related Drug Atlas

Drug(s) Targeting Intercellular adhesion molecule ICAM-1 (ICAM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
lifitegrast	DM4WVC5	Dry eye disease	9E1Z	Approved	[5]
BI-505	DMSZQHX	Multiple myeloma	2A83	Phase 2	[6]
APC-8015F	DM3VP19	Prostate cancer	2C82.0	Phase 2	[7]
AIC100	DMSPBOW	Thyroid cancer	2D10	Phase 1	[8]
GI-270384X	DM3KN2Q	Inflammatory bowel disease	DD72	Terminated	[9]
A-252444.0	DMDTA36	Inflammation	1A00-CA43.1	Terminated	[10]
MOR-102	DMRCH1M	Psoriasis vulgaris	EA90	Terminated	[11]
ISIS-1939	DMGN4OQ	Discovery agent	N.A.	Investigative	[12]

Drug(s) Targeting ICAM1 messenger RNA (ICAM1 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ISIS 1570	DMJ9G23	Lleum inflammation	1A40.0	Approved	[13]
INXC-ICAM1	DMODQW0	Transplant rejection	NE84	Terminated	[14]
A-286982	DM98VFW	Discovery agent	N.A.	Investigative	[15]
ISIS 11159	DM9V6FW	Discovery agent	N.A.	Investigative	[16]
ISIS 3224	DMAFEYG	Discovery agent	N.A.	Investigative	[16]
ISIS 1931	DMBMQNI	Discovery agent	N.A.	Investigative	[13]
PIPERROLEIN B	DMRVHWZ	Discovery agent	N.A.	Investigative	[17]
ISIS 2974	DM7K19L	Discovery agent	N.A.	Investigative	[13]
Dehydropipernonaline	DMIOA9M	Discovery agent	N.A.	Investigative	[17]
ISIS 3067	DMC9OL7	Discovery agent	N.A.	Investigative	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ICAM1 messenger RNA (ICAM1 mRNA)	TTA1L39	ICAM1_HUMAN	Not Available	[3]
Intercellular adhesion molecule ICAM-1 (ICAM1)	TTCT6F7	ICAM1_HUMAN	Antagonist	[4]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
• [3] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett. 2012 Jan 31;3(3):203-6.
• [6] A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15;23(4):502-15.
• [7] National Cancer Institute Drug Dictionary (drug id 561410).
• [8] Clinical pipeline report, company report or official report of AffyImmune Therapeutics.
• [9] Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96.
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012566)
• [11] Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model. Br J Dermatol. 2005 Oct;153(4):758-66.
• [12] Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem. 1991 Sep 25;266(27):18162-71.
• [13] US patent application no. 6,300,491, Oligonucleotide inhibition of cell adhesion.
• [14] ISIS 2302. INXC ICAM1, Oligo-TCS. Drugs R D. 1999 Jan;1(1):85-6.
• [15] Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5269-73.
• [16] US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
• [17] Alkamides from the fruits of Piper longum and Piper nigrum displaying potent cell adhesion inhibition. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4544-6.